Page last updated: 2024-11-05

ethylmalonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethylmalonic acid is a dicarboxylic acid with the formula C5H8O4. It is a white solid that is soluble in water. It is a structural isomer of glutaric acid. Ethylmalonic acid is synthesized by the reaction of diethyl malonate with ethyl bromide. Ethylmalonic acid is an important intermediate in the synthesis of many organic compounds, including pharmaceuticals, agricultural chemicals, and polymers. It is also used as a catalyst in organic reactions. Research into ethylmalonic acid is ongoing, and new applications are being discovered. Ethylmalonic acid can be used in the synthesis of 5-alkyl-2-pyrrolidinones, which are of interest in the field of pharmaceuticals and agricultural chemicals.'

ethylmalonic acid: don't confuse with diethyl malonate, which is a diester [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ethylmalonate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of ethylmalonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ethylmalonic acid : A dicarboxylic acid obtained by substitution of one of the methylene hydrogens of malonic acid by an ethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11756
CHEMBL ID1160009
CHEBI ID741548
SCHEMBL ID107241
MeSH IDM0114804

Synonyms (49)

Synonym
601-75-2
1,1-propanedicarboxylic acid
nsc96615
nsc-96615
malonic acid, ethyl-
propanedioic acid, ethyl-
ethylmalonic acid
.alpha.-carboxybutyric acid
inchi=1/c5h8o4/c1-2-3(4(6)7)5(8)9/h3h,2h2,1h3,(h,6,7)(h,8,9
ethylmalonic acid, 97%
ethylpropanedioic acid
2-ethylmalonic acid
CHEBI:741548 ,
2-ethylpropanedioic acid
alpha-carboxybutyric acid
BMSE000578
E0137
CHEMBL1160009
ethylmalonate
2-ethyl-propanedioic acid
LMFA01170105
AKOS005720903
STL146459
432nf49dfg ,
einecs 210-007-2
nsc 96615
unii-432nf49dfg
FT-0626351
SCHEMBL107241
2-ethyl-malonic acid
ethyl-malonic acid
2-ethylmalonic acid #
ethylmalonicacid
DTXSID00208842
J-521354
mfcd00002668
ethylmalonic acid, purum, >=97.0% (t)
a-carboxybutyrate
a-carboxybutyric acid
alpha-carboxybutyrate
1,1-propanedicarboxylate
CS-0022369
HY-34740
ethyl malonic acid
DS-5107
SY049007
BBL019763
AC1600
Q27225785

Research Excerpts

Overview

Ethylmalonic acid (EMA) is a major and potentially cytotoxic metabolite. EMA is associated with short-chain acyl-CoA dehydrogenase (SCAD) deficiency, a condition whose status as a disease is uncertain.

ExcerptReferenceRelevance
"Ethylmalonic acid is a metabolic organic acid, and its accumulation in urine is diagnostic of ethylmalonic aciduria. "( Capillary electrophoresis with capacitively coupled contactless conductivity detection for the determination of urinary ethylmalonic acid for the diagnosis of ethylmalonic aciduria.
Aktuğlu-Zeybek, AÇ; Cansever, MŞ; Kıykım, E; Özçelik, S; Öztekin, N, 2020
)
2.21
"Ethylmalonic acid (EMA) is a major and potentially cytotoxic metabolite associated with short-chain acyl-CoA dehydrogenase (SCAD) deficiency, a condition whose status as a disease is uncertain. "( Variants in the ethylmalonyl-CoA decarboxylase (ECHDC1) gene: a novel player in ethylmalonic aciduria?
Aagaard, L; Bie, A; Dipace, G; Fogh, S; Gregersen, N; Hansen, J; Kjeldsen, M; Mosegaard, S; Olsen, RKJ; Ribes, A; Van Schaftingen, E; Veiga-da-Cunha, M, 2021
)
2.29
"Ethylmalonic aciduria is a common finding in patients affected by short-chain acyl-CoA dehydrogenase (SCAD) deficiency and other diseases characterized by encephalopathy, muscular symptomatology, and lactic acidemia. "( Inhibition of the electron transport chain and creatine kinase activity by ethylmalonic acid in human skeletal muscle.
André, KR; Barschak, AG; Dutra Filho, CS; Ferreira, Gda C; Schuck, PF; Tonin, A; Vargas, CR; Viegas, CM; Wajner, M; Wannmacher, CM; Wyse, AT, 2006
)
2.01
"Ethylmalonic aciduria is a common biochemical finding in patients with inborn errors of short chain fatty acid beta-oxidation. "( Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase.
Andresen, BS; Bolund, L; Bross, P; Christensen, E; Corydon, MJ; Gregersen, N; Jensen, TG; Kmoch, S; Kristensen, TJ; Kølvraa, S; Lehnert, W; Martinez, G; Neve, S; Ribes, A; Rinaldo, P; Winter, V, 1996
)
3.18

Toxicity

ExcerptReferenceRelevance
" Therefore, ETHE1 is a mitochondrial sulfur dioxygenase involved in catabolism of sulfide that accumulates to toxic levels in ethylmalonic encephalopathy."( Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy.
Di Meo, I; Fagiolari, G; Hildebrandt, T; Levitt, MD; Mineri, R; Prelle, A; Rimoldi, M; Tiranti, V; Tiveron, C; Viscomi, C; Zeviani, M, 2009
)
0.35
" These results indicated that the toxic effect of IBI on striated muscle in beagle dogs is consistent with an inhibition of the mitochondrial flavin-containing enzymes including dimethyl glycine, sarcosine, isovaleryl-CoA, 2-hydroxyglutarate, and multiple acyl-CoA (short, medium, long, and very long chain) dehydrogenases."( Cannabinoid receptor antagonist-induced striated muscle toxicity and ethylmalonic-adipic aciduria in beagle dogs.
Achanzar, WE; Aranibar, N; Augustine, KA; Bennett, MJ; Brannen, KC; Carlson, KE; Charlap, JH; Dubrow, KM; Flint, OP; Horvath, JJ; Janovitz, EB; Kang, L; Kozlosky, JC; Megill, JR; Moulin, FJ; Ott, KH; Panzica-Kelly, JM; Patrone, LM; Rosini, LT; Tirmenstein, MA; Tomlinson, L; Zhang, H, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
dicarboxylic fatty acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Leucine, isoleucine and valine metabolism2470

Bioassays (1)

Assay IDTitleYearJournalArticle
AID164453Protein interaction energy by using binding affinity towards human L-xylulose reductase enzyme2003Bioorganic & medicinal chemistry letters, Apr-17, Volume: 13, Issue:8
Structure-based design of inhibitors of human L-xylulose reductase modelled into the active site of the enzyme.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (12.87)18.7374
1990's27 (26.73)18.2507
2000's31 (30.69)29.6817
2010's24 (23.76)24.3611
2020's6 (5.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.98 (24.57)
Research Supply Index4.64 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index98.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.98%)5.53%
Reviews2 (1.98%)6.00%
Case Studies39 (38.61%)4.05%
Observational0 (0.00%)0.25%
Other58 (57.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]